Core Viewpoint - Starz Entertainment Corp. (STRZ) has shown a significant price increase of 27.6% over the past four weeks, with a mean price target of $19.5 indicating a potential upside of 64.7% from its current trading price of $11.84 [1] Price Targets and Analyst Consensus - The average price target for STRZ consists of eight estimates ranging from a low of $12.00 to a high of $39.00, with a standard deviation of $9.9, indicating variability in analyst predictions [2] - The lowest estimate suggests a modest increase of 1.4%, while the highest estimate indicates a substantial upside of 229.4% [2] - A low standard deviation signifies a higher agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about STRZ's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 24.2%, with two estimates moving higher and no negative revisions [12] - STRZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, their reliability has been questioned, as they can mislead rather than guide investment decisions [3][7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Despite the skepticism surrounding price targets, the direction they imply can still serve as a useful guide for further research [10][14]

Core Viewpoint - Spruce Biosciences, Inc. (SPRB) has seen a 10.4% increase in share price over the past four weeks, closing at $64.3, with analysts suggesting a potential upside of 208.3% based on a mean price target of $198.25 [1] Price Targets and Analyst Estimates - The mean price target is derived from four short-term estimates, with a standard deviation of $61.58, indicating variability among analysts [2] - The lowest estimate of $140.00 suggests a potential increase of 117.7%, while the highest estimate predicts a surge of 340.1% to $283.00 [2] - Analysts' price targets should be approached with caution, as their reliability has been questioned historically [3][10] Earnings Estimates and Analyst Agreement - Analysts are increasingly optimistic about SPRB's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, two earnings estimates have been revised upward, leading to a 24.7% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - SPRB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Arcus Biosciences, Inc. (RCUS) shares have increased by 1.2% over the past four weeks, closing at $21.96, with a mean price target of $34.6 indicating a potential upside of 57.6% [1] - The average of 10 short-term price targets ranges from a low of $20.00 to a high of $52.00, with a standard deviation of $10.17, suggesting variability in analyst estimates [2] - Analysts are optimistic about RCUS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RCUS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Illinois Tool Works Inc. (ITW) is experiencing strong financial performance despite a price target set by Goldman Sachs indicating a potential downside for the stock [1][6]. Financial Performance - In Q4 2025, ITW's adjusted earnings per share (EPS) increased by 7% to $2.72, exceeding the Zacks Consensus Estimate of $2.68 [2][6]. - The company's revenues for Q4 reached $4.09 billion, marking a 4% increase from the previous year, driven by favorable foreign currency translation and strategic acquisitions [2][6]. - For the full year 2025, ITW reported net revenues of $16 billion, a 0.9% increase from the previous year, although adjusted EPS decreased by 10.4% to $10.49 [4]. Future Projections - ITW projects EPS for 2026 to be between $11.00 and $11.40, anticipating a 24% growth in revenue [3][6]. - The company plans to execute $1.5 billion in share buybacks, reflecting confidence in its financial health [3][6]. Market Position - ITW's stock is currently priced at $278.91, reflecting a 5.56% increase with a change of $14.70, and has fluctuated between $263.46 and $282.88 today [4]. - The stock has a 52-week high of $282.88 and a low of $214.66 [4]. - ITW's market capitalization stands at approximately $81.3 billion, with a trading volume of 3,188,697 shares today [5].

Group 1 - Day One Biopharmaceuticals, Inc. (DAWN) closed at $11.16, reflecting a 26.1% gain over the past four weeks, with a mean price target of $22.44 indicating a potential upside of 101.1% [1] - The average price target ranges from a low of $16.00 to a high of $29.00, with a standard deviation of $4.59, suggesting a variability in analyst estimates [2] - Analysts have shown increasing optimism regarding DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, with a 20.6% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - DAWN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts about the stock's price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a useful guide for potential price movement [14]

Core Viewpoint - Nuvation Bio Inc. (NUVB) shows potential for upside with a mean price target of $11.33, indicating a 32.1% increase from the current price of $8.58 [1] Price Targets and Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $2.78, indicating variability among analysts [2] - The lowest estimate is $8.00, suggesting a 6.8% decline, while the highest estimate is $18.00, indicating a potential surge of 109.8% [2] - Analysts' price targets should be approached with skepticism, as they may not accurately reflect future stock movements [3][10] Analyst Agreement and Earnings Estimates - Strong agreement among analysts regarding NUVB's ability to report better earnings than previously predicted supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has increased by 3.5% over the past month, with one estimate rising and no negative revisions [12] - NUVB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Implications of Price Targets - While the consensus price target may not be a reliable indicator of potential gains, the direction it implies can serve as a useful guide for further research [14]

Core Viewpoint - Amazon (AMZN) shares have increased by 3% over the past four weeks, closing at $227.35, with a mean price target of $295.8 indicating a potential upside of 30.1% according to Wall Street analysts [1]. Price Targets - The average of 54 short-term price targets ranges from a low of $230.00 to a high of $360.00, with a standard deviation of $24.81, suggesting variability in analyst estimates [2]. - The lowest estimate indicates a 1.2% increase from the current price, while the highest estimate suggests a 58.4% upside [2]. Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has remained stable, with no negative revisions and one estimate moving higher [12]. - AMZN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][10]. - Price targets can often be inflated due to business incentives of firms associated with the stocks [8]. - A low standard deviation in price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [9].

Core Viewpoint - Theravance Biopharma (TBPH) shares have increased by 1.7% over the past four weeks, closing at $18.79, with a mean price target of $26.71 indicating a potential upside of 42.2% according to Wall Street analysts [1] Price Targets - The average price target consists of seven estimates ranging from a low of $13.00 to a high of $42.00, with a standard deviation of $11.1, indicating variability among analysts [2] - The lowest estimate suggests a decline of 30.8% from the current price, while the highest estimate indicates a potential upside of 123.5% [2] Analyst Sentiment - Analysts are optimistic about TBPH's earnings prospects, as indicated by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 6.7% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - TBPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of TBPH's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - AvePoint, Inc. (AVPT) shows significant upside potential with a mean price target of $20, indicating a 49.3% increase from the current price of $13.4 [1] Price Targets and Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $4.07, suggesting variability in analyst predictions [2] - The lowest estimate is $16.00, indicating a 19.4% increase, while the highest estimate is $28.00, suggesting a 109% increase [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about AVPT's earnings, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 115.4%, with no negative revisions [12] - AVPT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Slide Insurance Holdings, Inc. (SLDE) has seen a 5.6% increase in share price over the past four weeks, closing at $16.89, with analysts suggesting a potential upside of 35% based on a mean price target of $22.8 [1] Price Targets - The average price target consists of five estimates ranging from a low of $21.00 to a high of $25.00, with a standard deviation of $2.05, indicating a potential increase of 24.3% to 48% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a positive indicator for investors [2][9] Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher for SLDE, which correlates with potential stock price increases [4][11] - Over the last 30 days, two earnings estimates have been revised upward, leading to a 15.4% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - SLDE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be prudent due to historical inaccuracies in predicting stock movements [3][7][10]